Shukra Pharmaceuticals Limited Stock Price Today (NSE: SHUKRAPHAR)
Fundamental Score
Shukra Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shukra Pharmaceuticals Limited share price today is ₹54.60, down 1.21% on NSE/BSE as of 16 September 2026. Shukra Pharmaceuticals Limited (SHUKRAPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.51K (Cr). The 52-week high for SHUKRAPHAR share price is ₹58.20 and the 52-week low is ₹41.40. At a P/E ratio of 68.59x, SHUKRAPHAR is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 28.89% and a debt-to-equity ratio of 0.06.
Shukra Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Shukra Pharmaceuticals Limited share price chart: 39.97% return over the past month. 52-week high ₹58.20, 52-week low ₹41.40.
Shukra Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹56.25 | ₹56.25 | ₹52.33 | ₹54.60 | 22.86L (Cr) | |
| ₹54.06 | ₹56.20 | ₹54.06 | ₹55.27 | 23.66L (Cr) | |
| ₹54.05 | ₹55.60 | ₹53.75 | ₹53.94 | 15.77L (Cr) | |
| ₹57.69 | ₹58.20 | ₹53.91 | ₹53.97 | 40.88L (Cr) | |
| ₹54.98 | ₹57.44 | ₹54.17 | ₹56.10 | 28.28L (Cr) | |
| ₹53.37 | ₹56.00 | ₹52.21 | ₹54.11 | 67.91L (Cr) | |
| ₹51.93 | ₹53.59 | ₹51.93 | ₹53.07 | 18.88L (Cr) | |
| ₹53.39 | ₹55.54 | ₹51.66 | ₹51.93 | 40.36L (Cr) | |
| ₹47.37 | ₹54.90 | ₹47.10 | ₹51.93 | 89.50L (Cr) | |
| ₹44.52 | ₹47.24 | ₹44.52 | ₹46.79 | 29.33L (Cr) |
Shukra Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹44.54 | ₹58.20 | ₹44.34 | ₹54.60 | +22.59% | |
| ₹30.26 | ₹46.99 | ₹29.93 | ₹44.39 | +46.70% | |
| ₹28.72 | ₹36.50 | ₹28.50 | ₹30.18 | +5.08% | |
| ₹29.00 | ₹34.34 | ₹28.13 | ₹28.72 | -0.97% | |
| ₹29.38 | ₹35.30 | ₹26.30 | ₹28.99 | -1.33% | |
| ₹30.34 | ₹36.85 | ₹28.13 | ₹29.07 | -4.19% | |
| ₹39.20 | ₹45.33 | ₹30.34 | ₹30.34 | -22.60% | |
| ₹39.18 | ₹46.79 | ₹34.15 | ₹41.24 | +5.26% | |
| ₹56.29 | ₹58.99 | ₹38.59 | ₹40.51 | -28.03% | |
| ₹38.68 | ₹65.26 | ₹36.70 | ₹59.25 | +53.18% | |
| ₹40.19 | ₹44.31 | ₹35.73 | ₹38.68 | -3.76% | |
| ₹35.15 | ₹42.70 | ₹32.44 | ₹41.01 | +16.67% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Shukra Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shukra Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SHUKRAPHAR across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (28.89%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (36.91%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (28.42%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (38.37% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (175.29% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (175.08% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (27.40x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.79)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (50.96%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Premium Valuation Risk (P/E: 68.59x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (38.05x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-132.10%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-52.52%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-9.24 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Shukra Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Shukra Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Shukra Pharmaceuticals LimitedShukra Pharmace...Selected✓ SHUKRAPHAR • 524632 | 55.3/100 | ₹54.60₹55 | ₹1512.44₹1512.44 | 68.59Average 68.6 Average | 28.89%Excellent 28.89% Excellent | 36.91%Excellent 36.91% Excellent | 0.06Excellent 0.1 Excellent | 175.08%Excellent 175.08% Excellent | 38.37%Excellent 38.37% Excellent | 0.03% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Shukra Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for SHUKRAPHAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹4.23 | ₹13.64 | 3.2x |
| FY 2023 | ₹0.66 | ₹3.09 | 4.7x |
| FY 2022 | ₹0.02 | ₹3.30 | 132.5x |
| FY 2021 | ₹0.01 | ₹2.08 | 333.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Shukra Pharmaceuticals Limited Dividend History
Annual cash dividends paid by SHUKRAPHAR — dividend yield 0.03%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.38 Cr |
| FY 2024 | ₹0.07 Cr |
| FY 2023 | ₹0.07 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Shukra Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for SHUKRAPHAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-52.52%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-132.10%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
38.37%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
175.08%
Compounded annual net profit growth over 5 years
Shukra Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SHUKRAPHAR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Shukra Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Shukra Pharmaceuticals Limited (SHUKRAPHAR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Shukra Pharmaceuticals Limited
About SHUKRAPHAR (Shukra Pharmaceuticals Limited)
Shukra Pharmaceuticals Ltd is an Indian pharmaceutical company focused on developing, manufacturing, and selling a broad range of medicines both in India and to other countries. Th...ey create and market various types of drugs, including those that fight infections like bacteria and fungi, as well as treatments for malaria, viruses, and parasitic worms. Their product range also extends to medicines for mental health conditions such as depression and anxiety, and treatments for common ailments like ulcers and high blood pressure. The company's main business areas are centered around providing affordable and accessible medicines across diverse therapeutic categories. They make many kinds of products including antibiotics (like penicillin), vitamins, and medications for allergies, diabetes, and tuberculosis. This wide variety helps them reach different segments of the healthcare market and cater to many patient needs. While not one of the very largest pharmaceutical companies, Shukra Pharmaceuticals holds a significant position in the Indian market by supplying essential medicines. Based in Ahmedabad, the company has been operating since 1993 and continues to develop and distribute pharmaceutical products aimed at improving health outcomes. They aim to continue their growth within India's competitive pharmaceuticals sector.
Company Details
Key Leadership
SHUKRAPHAR Share Price: Frequently Asked Questions
What is the current share price of Shukra Pharmaceuticals Limited?
Shukra Pharmaceuticals Limited (SHUKRAPHAR) trades at ₹54.60 on NSE and BSE. Market cap ₹1.51K (Cr). Educational data only.
What is the P/E ratio of Shukra Pharmaceuticals Limited?
Shukra Pharmaceuticals Limited has a P/E of 68.59x vs industry average 34.89x.
What is the Bull Run score for Shukra Pharmaceuticals Limited?
Shukra Pharmaceuticals Limited has a Bull Run score of 55.3/100 based on 25+ financial parameters.
Does Shukra Pharmaceuticals Limited pay dividends?
Shukra Pharmaceuticals Limited has a dividend yield of 0.03%. Past dividends don't guarantee future payments.
What is the ROE of Shukra Pharmaceuticals Limited?
Shukra Pharmaceuticals Limited has ROE of 28.89%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Shukra Pharmaceuticals Limited?
Shukra Pharmaceuticals Limited has debt-to-equity of 0.06.
Is Shukra Pharmaceuticals Limited a good investment?
Bull Run gives Shukra Pharmaceuticals Limited a score of 55.3/100. This is not investment advice — consult a SEBI-registered advisor.